- "The misfortune of some makes the happiness of others" goes an old saying.
- In this case, high COVID-19 infection rates have been a boon for companies like Co-Diagnostics and their investors.
- Further rise in infection rates may just be the trigger needed to boost the stock price but beware, as there are others in the same business too.
- Moreover, despite a lawsuit filed against CODX, the company's Logix testing kit is still present in the FDA's list.
- Given the high percentage of a short position, it would be better to be on the sidelines and wait for an update concerning the lawsuit.
For further details see:
Co-Diagnostics: Diversified In COVID-19 Diagnostics